Drug intelligence / Profile preview

Chimigen SARS-CoV-2 vaccine

Development stage: Preclinical
Lead developer: Kaimi Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics

Overview

Chimigen SARS-CoV-2 vaccine is an investigational **prophylactic COVID-19 vaccine** being developed by **Akshaya Bio** using its proprietary **Chimigen** platform. The candidate is designed to prevent infection by **SARS-CoV-2** through **dendritic cell receptor-targeted chimeric molecules** that combine antigen and antibody components to mimic antigen-antibody immune complex biology and enhance uptake by antigen-presenting cells such as dendritic cells. The chimeric antigen is reported to be manufactured in **insect cells**, which may contribute additional immunogenicity, and Akshaya Bio disclosed collaboration with **Cytovance Biologics** for GMP scale-up manufacturing support.

Other names: Chimigen SARS-CoV-2 vaccine

Beyond the preview

Go deeper on Chimigen SARS-CoV-2 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chimigen SARS-CoV-2 vaccine.

Explore the full profile